scholarly journals Beneficial effects of botulinum toxin type A in trigeminal neuralgia

2008 ◽  
Vol 66 (3a) ◽  
pp. 500-503 ◽  
Author(s):  
Carlos Zúñiga ◽  
Sergio Díaz ◽  
Fabián Piedimonte ◽  
Federico Micheli
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Clinical Effects ◽  
Beneficial Effects ◽  
Pain Syndromes ◽  
Idiopathic Trigeminal Neuralgia ◽  
Botulinum Toxin Injections

Botulinum toxin has been thoroughly studied as a potential tool in the treatment of several pain syndromes. Therefore, we assessed the clinical effects of botulinum toxin type A injections in 12 patients with otherwise unresponsive idiopathic trigeminal neuralgia. Patients were infiltrated with 20-50 units of botulinum toxin in trigger zones. Those who presented with mandibular involvement were also infiltrated in the masseter muscle. The patients were assessed on a weekly basis using the Visual Analogic Scale for pain. Ten of our patients reported a significant benefit from botulinum toxin injections, with reduction or even disappearance of pain, and remained pain free for as long as 60 days. Our findings suggest that botulinum toxin may represent a useful therapeutic tool in the management of patients with this entity.

scholarly journals Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Jing Liu ◽  
Ying-Ying Xu ◽  
Qi-Lin Zhang ◽  
Wei-Feng Luo
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Advanced Age ◽  
Efficacy And Safety ◽  
Younger Patients ◽  
Idiopathic Trigeminal Neuralgia ◽  
D Values

Objective. To assess the therapeutic efficacy and safety of botulinum toxin type A (BTX-A) for treating idiopathic trigeminal neuralgia (ITN) in patients ≥80 years old. Methods. Selected patients n=43 with ITN, recruited from the neurology clinic and inpatient department of the Second Affiliated Hospital of Soochow University between August 2008 and February 2014, were grouped by age, one subset n=14 ≥80 years old and another n=29 <60 years old. Each group scored similarly in degrees of pain registered by the visual analogue scale (VAS). Dosing, efficacy, and safety of BTX-A injections were compared by group. Results. Mean dosages of BTX-A were 91.3 ± 25.6 U and 71.8 ± 33.1 U in older and younger patients, respectively t=1.930, p=0.061. The median of the VAS score in older patients at baseline (8.5) declined significantly at 1 month after treatment (4.5) p=0.007, as did that of younger patients (8.0 and 5.0, resp.) p=0.001. The median of the D values of the VAS scores did not differ significantly by group (older, 2.5; younger, 0; Z=−1.073, p=0.283). Two patients in each group developed minor transient side effects p=0.825. Adverse reactions in both groups were mild, resolving spontaneously within 3 weeks. Conclusions. BTX-A is effective and safe in treating patients of advanced age (≥80 years old) with ITN, at dosages comparable to those used in much younger counterparts (<60 years old).

APPLICATION OF BOTULINUM TOXIN TYPE A FOR PAIN REDUCTION IN TRIGEMINAL NEURALGIA - 6 - MONTH FOLLOW-UP

2021 ◽  
pp. 15-19
Author(s):  
Maristela Corrêa de Lima ◽  
Célia Marisa Rizzatti Barbosa ◽  
Paulo Henrique Ferreira Caria
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Pain Reduction

Injections of Botulinum Toxin Type A Produce Pain Alleviation in Intractable Trigeminal Neuralgia

2005 ◽  
Vol 21 (2) ◽  
pp. 182-184 ◽  
Author(s):  
Nasser Allam ◽  
Joaquim P. Brasil-Neto ◽  
Gilberto Brown ◽  
Carlos Tomaz
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: a better therapeutic effect

2019 ◽  
Vol Volume 12 ◽  
pp. 2177-2186 ◽  
Author(s):  
Shouyi Wu ◽  
Yajun Lian ◽  
Haifeng Zhang ◽  
Yuan Chen ◽  
Chuanjie Wu ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Therapeutic Effect ◽  
Older Patients ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals Role of Botulinum Toxin Type-A (BTX-A) in the Management of Trigeminal Neuralgia

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Gaurav Verma
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Review Of The Literature ◽  
The Past ◽  
Permanent Cure ◽  
Variable Success

Trigeminal neuralgia (TN) is a clinical condition characterized by paroxysmal attacks of severe and electric shock-like pain along the distribution of one or more branches of the trigeminal nerve. Various medicinal or surgical modalities have been employed in the past with variable success. Newer methods were tried in search of permanent cure or long-lasting pain relief. The purpose of this paper is to present the review of the literature regarding the use of botulinum toxin type-A (BTX-A) in the management of trigeminal neuralgia.

Sign in / Sign up

Export Citation Format

Share Document